Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.

Oliver GrossJan BoeckhausLutz T WeberHiddo J Lambers HeerspinkJames F SimonRees AhmedChristoph GerstUlrike DuerrFlorian WalkerRalf TostmannJürgen HelmThomas AsendorfTim Friede

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

DOUBLE PRO-TECT Alport will assess whether SGLT2-inhibitors can safely reduce change from baseline in UACR as a marker for progression of CKD in young patients living with AS.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
young adults
clinical trial
newly diagnosed
randomized controlled trial
anti inflammatory
prognostic factors
study protocol
phase iii
patient reported
genetic diversity